Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

Metastatic Lung Cancer Clinical Trial

— ICARUS-LUNG01  

Official title:

Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04940325
• Other study ID #: 2020-005723-37
• Secondary ID: 2020/3187
• Status: Recruiting
• Phase: Phase 2
• Start date: May 12, 2021
• Est. completion date: November 12, 2025

Study information

• Verified date: June 2021
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: Babara Pistili, Dr
• Phone: +33 (0)1 42 11 42 11
• Email: barbara.pistilli[@]gustaveroussy.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy and safety of DS-1062a in participants with metastatic, unresectable NSCLC having progressed on one, but not more than three previous standard therapies. Moreover, the immune effects, the predictors of resistance and response to treatment, the effect of the chemotherapy on deoxyribonucleic acid (DNA) replication will be assessed and will help identify the subgroups that will mostly benefit from the treatment. The pharmacokinetics of the product and the anti-drug antibody (ADA) will be also evaluated. A total of 100 participants are planned to be included in the study. Participants will receive, every three weeks, a dose of DS-1062a equivalent to 6 mg/kg of body weight until progression or until unacceptable toxicity. Tumor evaluation will be performed every six weeks by the mean of a computed tomography for the thorax, abdomen and pelvis (TAP CT-scan) or a magnetic resonance imaging (MRI). Brain and/or bone CT scans will be also performed throughout the study for participants with brain and/or bone metastasis. The safety of the product will be assessed at each cycle, through complete clinical exams, biological tests, electrocardiograms (ECGs), cardiac echographies (ECHOs) and through the collection of ongoing toxicities or adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 12, 2025
• Est. primary completion date: November 12, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants with histologically confirmed diagnosis of advanced and/or unresectable NSCLC
• Participants who received at least one line and not more than three lines of therapy and considered by the investigator as refractory to standard treatment or for which no

standard treatment is available:

1. Participants who have no known mutation or mutation without an approved targeted therapy: anti programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) containing therapy and a platinum-doublet regimen

2. Participants who have known EGFR, BRAF, and MET mutation or ALK, ROS1, RET, NTRK fusion: one line of an approved targeted agent and one platinum-doublet regimen

• Metastatic site easily accessible to biopsy (with exception of bone metastasis)
• Presence of at least one measurable lesion (different from the biopsy site) according to RECIST v1.1
• ECOG status should be equal or less to one
• Life expectancy should be equal or more than 3 months
• Participants must have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to Cycle 1, Day 1
• Participants with asymptomatic and clinically stable treated brain metastasis, who require no treatment with corticosteroids and/or anticonvulsants. Participants must have a stable neurologic status for at least two weeks prior to Cycle 1 Day 1
• Females of reproductive/childbearing potential must have a negative serum pregnancy test at screening and must agree to use a highly effective form of contraception or avoid intercourse during the study and for at least 7 months after the last dose of study drug

Contraceptive methods considered highly effective:

1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)

2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)

3. Intrauterine device (IUD)

4. Intrauterine hormone-releasing system (IUS)

5. Bilateral tubal occlusion

6. Vasectomized partner

7. Complete sexual abstinence during and for at least 7 months after the last dose of study drug. Female participants must not donate, or retrieve for their own use, ova from the time of screening and for at least 7 months after the final study drug administration Male participants must be surgically sterile or must withhold heterosexual intercourse or must be willing to use a highly effective birth control upon enrollment, during the treatment period, and for at least 4 months following the last dose of study drug. Male participants must not freeze or donate sperm from screening and for at least 4 months after the final study drug administration.

• Participants must understand, sign and date the written informed consent from prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol
• Participants must be affiliated to a Social Security System or beneficiary of the same

Exclusion Criteria:

• Participants unwilling to participate to the biological investigations and to perform biopsies and blood sample collection as required in the protocol
• Participants with only bone metastasis will be excluded, except if they have an accessible primary tumor which could be biopsied at baseline, on-treatment and end-of-treatment.
• Participant with any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during screening.
• Participant with clinically severe pulmonary compromise (based on investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited

to:

1. Any underlying pulmonary disorder

2. Any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement

3. OR prior pneumonectomy

• Participants receiving chronic systemic corticosteroids at a dose higher than 10 mg prednisone or equivalent or any form of immunosuppressive therapy prior to Cycle 1 Day

1. Participants who require use of bronchodilators, inhaled steroids, or local steroid injections may be included in the study

• Participants with evidence of any leptomeningeal disease
• Participants with evidence of clinically active spinal cord compression or brain metastases
• Participants with a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients (including but not limited to polysorbate 80) of DS-1062a
• Participants with a history of severe hypersensitivity reactions to other monoclonal antibodies
• Inadequate washout period prior to Cycle 1 Day 1, defined as:

1. Whole brain radiation therapy within 14 days before treatment or stereotactic brain radiation therapy, within 7 days before treatment

2. Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)), within 14 days before treatment or 5 half-lives, whichever is longer

3. Immune checkpoint inhibitor therapy, within 21 days before treatment

4. Major surgery (excluding placement of vascular access), within 28 days before treatment

5. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation, within 28 days before treatment or palliative radiation therapy within 14 days before treatment

6. Chloroquine or hydroxychloroquine within 14 days before treatment

7. Live virus vaccination, within 28 days before treatment

• Prior treatment with an anti-TROP-2 antibody including study drug
• Participant previously treated with an antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I inhibitor
• Participant with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved according to the NCI-CTCAE v5.0, grade 2 or less
• Any evidence of primary malignancy other than locally advanced or metastatic lung cancer within three years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
• Participant with clinically significant corneal disease
• Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol
• Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1, including:

1. Corrected QT interval higher than 470 ms for females and 450 ms for males according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apart

2. Left ventricular ejection fraction (LVEF) less than 50% by either ECHO or Multigated Acquisition Scan (MUGA)

3. Uncontrolled hypertension (resting systolic blood pressure higher than 180 mmHg or diastolic blood pressure higher than 110 mmHg)

4. Myocardial infarction within six months

5. NYHA Classes 2 to 4 within 28 days before treatment

6. Uncontrolled angina pectoris within six months.

7. Cardiac arrhythmia requiring antiarrhythmic treatment

• Active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1, Day 1.

Participants with past or resolved hepatitis B virus (HBV) infection are eligible if:

1. Hepatitis surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR

2. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases (in the absence of liver metastasis); OR

3. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with liver metastasis and abnormal transaminases AST/ALT less than 3 ULN

4. Participants with a history of Hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection, is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer)

• Participants with known human immunodeficiency virus (HIV) or active COVID-19 infection
• Female participants who are pregnant or breastfeeding or intend to become pregnant during the study Participants with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial Participants under guardianship or deprived of his/her liberty by a judicial or administrative decision or incapable of giving his/her consent
• Participation in another clinical trial evaluating an experimental drug (except non-interventional research)

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Metastatic Lung Cancer

Intervention

Drug:
• DS-1062a
First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)

Locations

Country	Name	City	State
France	Gustave Roussy	Villejuif

Sponsors (2)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris	Daiichi Sankyo, Inc.

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To assess physical functioning sub-scale score of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) based on a scale from 1 to 4, where higher scores mean worse outcome		During treatment (Cycles 1, 2, 3 and then every 2 cycles), at EoT and then up to 3 years after EoT, an average of 40 months]
Other	To assess global health sub-scale score of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) based on a scale from 1 to 7, where higher scores mean better outcome		During treatment (Cycles 1, 2, 3 and then every 2 cycles), at EoT and up to 3 years after EoT, an average of 40 months]
Primary	Evaluation of objective response rate (ORR)	ORR is defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) observed on treatment and assessed by investigators	During treatment period, an average of 4 months
Secondary	Evaluation of duration of response (DoR)	Defined as the time from the first documented CR or PR until the date of disease progression, or until the date of death	From cycle 2 (Week 3) up to 3 years after the EoT, an average of 39 months]
Secondary	Evaluation of progression free Survival (PFS)	Defined as the time date of the first dose until progression or death from any cause, whichever occurs first	From cycle 2 (Week 3) up to 3 years after the EoT, an average of 39 months]
Secondary	Evaluation of clinical benefit ratio (CBR)	Defined as the presence of at least a PR or CR, or a stable disease (SD) for more than six months under treatment	During treatment period, an average of 4 months
Secondary	To evaluate incidence of adverse events (AEs)	All adverse events (AEs), treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)	During treatment (at each cycle), at EoT and up to 35 days after EoT, an average of 5 months]
Secondary	To evaluate proportion of treatment modification	Treatment discontinuation, interruptions and dose reductions	During treatment, an average of 4 months
Secondary	Incidence of abnormal laboratory test results		During treatment (at each cycle) and at EoT, an average of 4 months
Secondary	To evaluate incidence of abnormal ECG readings		During treatment (at each cycle) and at EoT, an average of 4 months
Secondary	To evaluate change in left ventricular ejection fraction (LVEF)		During treatment and at EoT, an average of 4 months
Secondary	To assess changes in Eastern Cooperative Oncology Group performance status [ECOG PS] based on a score from 1 to 5, where higher scores mean worse outcomes		During treatment (at each cycle) and at EoT, an average of 4 months